CTIS2023-507030-24-00进行中（未招募）1 期
A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Phase 2/3 Study to Evaluate the Safety and Efficacy of NEXAGON ® (Lufepirsen Ophthalmic Gel) in Subjects with Persistent Corneal Epithelial Defects (NEXPEDE-1) - AMB-01-006
Amber Ophthalmics Inc.0 个研究点目标入组 120 人开始时间: 2023年12月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •male or female •Who are at least 2 years of age (US only) • Who are at least 18 years of age (all other countries), the presence of a corneal epithelial defect that is at least 2 weeks in duration and refractory to one or more conventional non-surgical standard of care (SOC) treatments, as assessed by the Investigator, must have no clinical evidence of improvement in corneal epithelial defect within 2 weeks prior to randomization despite the use of non-surgical SOC treatment, as assessed by the Investigator, an epithelial defect measuring at least 2 mm along the largest diameter at Day 1 of the Treatment Period, subjects or their legally authorized representative(s) must have the ability to provide written informed consent, and must do so, prior to participation in any study-related procedures, female subjects with childbearing potential must be 1-year postmenopausal, surgically sterilized, or have a negative urine pregnancy test at Visit 1 and 2; women of childbearing potential must use an acceptable form of contraception throughout the study. Adequate birth control methods, including but not limited to, abstinence, stabilized on hormonal contraception [i.e., a) oral or patch/transdermal contraceptives for at least one full cycle (e.g., one or two months), or b) implant, injection, vaginal ring (e.g., NuvaRing®) for at least one week, intrauterine device (IUD) for at least one week, condom and a spermicidal, diaphragm and a spermicidal, or sterile solitary partner (vasectomy performed at least six months prior), must have the ability and willingness to comply with all study procedures
排除标准
- •any known ocular infection(s) that are deemed to be active (bacterial, viral, fungal and/or protozoal) requiring therapeutic intervention at the time of randomization in the affected eye(s), a known hypersensitivity to one of the components of the study or procedural medications (e.g., NEXAGON, fluorescein), participated in an interventional clinical drug or device trial within 28 days prior to Day 1, use of the medications presented in the table below are prohibited in the study., a corneal surface defect in either eye that is directly attributed to an infectious etiology (bacterial, viral, fungal and/or protozoal) that has not fully resolved and/or treatment has not been completed, evidence of corneal ulceration/melting involving the posterior third of the stroma and/or perforation in either eye, blepharitis or meibomian gland disease in the study eye that is deemed to be clinically relevant and/or active (i.e., requiring mechanical lid hygiene = once a week or systemic treatment for blepharitis associated with MGD), history of a full thickness keratoplasty, > 1 Descemet membrane endothelial keratoplasty (DMEK) or Descemet’s stripping endothelial keratoplasty (DSEK) procedure, history of ocular surgery or any ocular procedure(s) not meeting the designated washout time prior to Day 1 of the study, any other ocular disease requiring topical ocular medication in the affected eye during the course of the study treatment period, a Schirmer I test result (without anesthesia) of = 3 mm/5 minutes in the study eye, a presence or history of any ocular or systemic disorder or condition that could interfere with the safety or efficacy of the study treatment, or the interpretation of the study results. Such degenerative and/or progressing ocular or systemic disorders are, but not limited to: lagophthalmos, uveitis, optic neuritis, poorly controlled diabetes, autoimmune disease, active systemic infection, neoplastic diseases
研究者
相似试验
进行中（未招募）
1 期
A multicenter, randomized, double masked, controlled by vehicle, to assess safety and the efficacy of the ophthalmic solution, SYD-101, for the treatment of Myopia in ChildreMedDRA version: 20.0Level: PTClassification code 10028651Term: MyopiaSystem Organ Class: 10015919 - Eye disordersMyopiaEUCTR2018-004775-13-SKSydnexis, Inc.840
进行中（未招募）
1 期
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled Study to Assess the Safety and Efficacy of SYD-101 Ophthalmic Solution for the Treatment of Myopia in ChildreMedDRA version: 20.0Level: PTClassification code: 10028651Term: Myopia Class: 100000004853MyopiaCTIS2023-509134-19-00Sydnexis Inc.852
进行中（未招募）
1 期
A multicenter, randomized, double masked, controlled by vehicle, to assess safety and the efficacy of the ophthalmic solution, SYD-101, for the treatment of Myopia in ChildreMedDRA version: 20.0Level: PTClassification code 10028651Term: MyopiaSystem Organ Class: 10015919 - Eye disordersMyopiaEUCTR2018-004775-13-ATSydnexis, Inc.840
尚未招募
3 期
A study to test a drug for the treatment of pterygiumCTRI/2024/01/061151Cloudbreak Therapeutics,
进行中（未招募）
不适用
epafenac Once Daily for Macular Edema - Study 2EUCTR2013-001874-12-ESAlcon Research, Ltd590